BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34016721)

  • 21. Biphasic response of NK cells expressing both activating and inhibitory killer Ig-like receptors.
    Warren HS; Campbell AJ; Waldron JC; Lanier LL
    Int Immunol; 2001 Aug; 13(8):1043-52. PubMed ID: 11470774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL.
    Bakker AB; Phillips JH; Figdor CG; Lanier LL
    J Immunol; 1998 Jun; 160(11):5239-45. PubMed ID: 9605119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
    Guo KY; Mei JZ; Yao KT
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective inhibition of human and mouse natural killer tumor recognition using retroviral antisense in primary natural killer cells: involvement with MHC class I killer cell inhibitory receptors.
    Ortaldo JR; Mason AT; Mason LH; Winkler-Pickett RT; Gosselin P; Anderson SK
    J Immunol; 1997 Feb; 158(3):1262-7. PubMed ID: 9013968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients.
    Konjević G; Mirjacić Martinović K; Vuletić A; Jović V; Jurisić V; Babović N; Spuzić I
    Clin Exp Metastasis; 2007; 24(1):1-11. PubMed ID: 17295095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
    Ewen EM; Pahl JHW; Miller M; Watzl C; Cerwenka A
    Eur J Immunol; 2018 Feb; 48(2):355-365. PubMed ID: 29105756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
    Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
    Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis of HLA-C recognition by p58 natural killer cell inhibitory receptors.
    Kim J; Chwae YJ; Kim MY; Choi IH; Park JH; Kim SJ
    J Immunol; 1997 Oct; 159(8):3875-82. PubMed ID: 9378975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.
    Carrega P; Pezzino G; Queirolo P; Bonaccorsi I; Falco M; Vita G; Pende D; Misefari A; Moretta A; Mingari MC; Moretta L; Ferlazzo G
    PLoS One; 2009 Dec; 4(12):e8132. PubMed ID: 19997637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The actin cytoskeleton controls the efficiency of killer Ig-like receptor accumulation at inhibitory NK cell immune synapses.
    Standeven LJ; Carlin LM; Borszcz P; Davis DM; Burshtyn DN
    J Immunol; 2004 Nov; 173(9):5617-25. PubMed ID: 15494512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NK cell killer Ig-like receptor repertoire acquisition and maturation are strongly modulated by HLA class I molecules.
    Sleiman M; Brons NH; Kaoma T; Dogu F; Villa-Forte A; Lenoble P; Hentges F; Kotsch K; Gadola SD; Vilches C; Zimmer J
    J Immunol; 2014 Mar; 192(6):2602-10. PubMed ID: 24554773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel antibody combination to identify KIR2DS2
    Blunt MD; Rettman P; Bastidas-Legarda LY; Fulton R; Capizzuto V; Naiyer MM; Traherne JA; Khakoo SI
    HLA; 2019 Jan; 93(1):32-35. PubMed ID: 30381896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells.
    Vineretsky KA; Karagas MR; Christensen BC; Kuriger-Laber JK; Perry AE; Storm CA; Nelson HH
    Cancer Res; 2016 Jan; 76(2):370-6. PubMed ID: 26744525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 4.
    Katz G; Markel G; Mizrahi S; Arnon TI; Mandelboim O
    J Immunol; 2001 Jun; 166(12):7260-7. PubMed ID: 11390475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
    Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
    Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
    Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
    Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discrimination between the main activating and inhibitory killer cell immunoglobulin-like receptor positive natural killer cell subsets using newly characterized monoclonal antibodies.
    David G; Morvan M; Gagne K; Kerdudou N; Willem C; Devys A; Bonneville M; Folléa G; Bignon JD; Retière C
    Immunology; 2009 Oct; 128(2):172-84. PubMed ID: 19740374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
    Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
    Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells.
    Joncker NT; Raulet DH
    Immunol Rev; 2008 Aug; 224():85-97. PubMed ID: 18759922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.